F OLLOWING an attack of acute coronary thrombosis and/or myocardial infarction certain patients were selected to continue the use of dicumarol for the "long term" in the hope of preventing recurrent attacks. The premonitory signs of an acute attack are often absent and when present are frequently misinterpreted except in retrospect, and as no method of selecting the critical time to administer anticoagulants as a preventive measure is known, dicumarol must be used continuously in any attempt to forestall recurrent coronary thrombosis. The fear that coronary artery intimal hemorrhage induced by dicumarol might play a significant part in the pathogenesis of recurrent coronary thrombosis in patients taking dicumarol continuously has been allayed by the failure to discover any significant incidence of coronary subintimal hemorrhage at autopsy in individuals treated with anticoagulants, both in the study of 90 autopsy subjects by the American Heart Association "Committee for the Evaluation of Anticoagulants in the Treatment of Coronary Thrombosis with Myocardial Infarction,"' and in careful histologic studies* of 22 brain thromboplastin (Difco) being employed; in many of the patients the Link-Shapiro modification with the use of a commercial rabbit-lung thromboplastin (Maltine), served as a "double-check" to insure technical adequacy. We doubt that estimating prothrombin activity by the two-stage method of Warner, Brinkhaus, and Smith will prove to be a safer guide in dosage. The question of the optimal depression of prothrombin activity is not settled. Brambel and co-workers2 have had excellent clinical results in 3,304 postoperative patients with depression of prothrombin activity to only 40 to 50 per cent, with virtually no serious hemorrhage. Our own observations, and the experience of others,3 4 suggests, however, that thrombo-embolization is more likely to occur if the prothrombin activity exceeds 30 per cent of normal than if it is in the 10 to 30 per cent bracket. It is less confusing to compute dosage with reference to the prothrombin time in seconds rather than percentage of prothrombin activity. Shapiro and Weiner5 state: "It seems to us that to follow adequately the prothrombin response to 'dicumarol,' the clinician should know the normal range of the thromboplastin used and the therapeutic range he wishes to establish in terms of time. With this knowledge the calculation of percentage is superfluous; without it the percentage figure is misleading." For practical purposes we advocate using sufficient dicumarol to maintain the prothrombin time at two to two and one-half times the normal, which in our laboratory permits a range of twentyfour to thirty-eight seconds (the average normal prothrombin time with the technique used being 13.5 + 1.5 seconds). Comparison with serial dilution curves shows that the range of twenty-four to thirty-eight seconds is equivalent to 30 to 10 per cent prothrombin activity.
After the first three weeks, prothrombin tests were made at four-day intervals, and this was gradually extended to seven-day and even ten-to fourteen-day intervals after several months in some patients. Only reasonably intelligent patients were selected and all were well informed concerning the purpose of treatment with dicumarol and the risk if directions were not followed. Urinalysis was performed at least once a month and liver function studies were made approximately every six months.
Clinical description of 78 patients given dicumarol prophylactically for periods ranging from three to sixty-two months follows: Forty-four patients received dicumarol for three to twelve months, twentythree for twelve to twenty-four months, 8 patients for twenty-four to thirty-six months, 2 for thirtysix to forty-eight months, and one for sixty-two months. There were 12 patients under 50 years of age, 34 between 50 and 60 years, and 32 between 60 and 75 years. Thirty-three patients had experienced more than one attack of coronary thrombosis. Seventeen patients were not placed on the regimen until some time after their acute attack, when, because of increasing angina or acute coronary insufficiency, dicumarol therapy was started. Five cases included in this study were the subject of a preliminary report by Nichol and Fassett;6 of these, 2 fatal cases are described and the clinical sequel of 3 patients still living is given.
RESULTS
In 9 patients therapy was discontinued after three to twenty-three months in 2 because of change in residence, in four because of lack of cooperation or difficulty in obtaining prothrombin determinations, and in 3 because of hemorrhagic complications (see belowv). Twelve patients, or 15.3 per cent of the group, died while under treatment-in 4 death was due to recurrent attacks of coronary thrombosis; in 6 it was ascribed to either acute coronary insufficiency, congestive heart failure, or "cessation of cardiac activity" (probably ventricular fibrillation or ventricular standstill). Cerebral Case 3. The patient, J. L., aged 53 years, had acute coronary thrombosis, but dicumarol therapy was discontinued on the tenth day because of hematuria due to hemorrhagic urethritis from an indwelling catheter, requiring transfusion. Femoral phlebothrombosis and pulmonary embolism occurred three weeks later, following which dicumarolization was successfully used for five months until May 12, 1947 , when death occurred one hour after the patient experienced acute substernal pain. Prothrombin time seven days prior to death was twenty-seven seconds (20 per cent PA). Autopsy showed old myocardial infarction and a red thrombus (?) in the posterior descending coronary branch and left pleural adhesions. Death was attributed to acute coronary thrombosis, although microscopic studies failed to confirm thrombus formation.
Case 4.-The patient, F. B.,t aged 65 years, developed his second coronary thrombosis in April 1946, at which time dicumarol therapy was started. Intraventricular block and congestive heart failure were present. In December 1946, gross hematuria appeared when prothrombin time was twenty-eight seconds (19 per cent PA), and bleeding from hemorrhoids occurred in October 1947. Two months later when the prothrombin time was twenty-seven seconds (20 per cent PA) he developed more acute congestive heart failure with nodal tachycardia, but no electrocardiographic evidence of fresh myocardial infarction followed. Abdominal tenderness and distention developed. Right thoracentesis yielded 700 c.c. of straw-colored fluid one week prior to death, which occurred after twenty-one months of dicumarol therapy, when the prothrombin time was thirty seconds (15 per cent PA). Autopsy showed cardiac hypertrophy, left ventricular aneurysm, and the coronary arteries occluded at many points, but no fresh infarction was found. Right hemothorax, bilateral bronchiectasis, bronchopneumonia, and hypertensive arterial changes in the kidneys were found. The liver showed passive congestion and a lymphangioma containing pin-point areas of hemorrhage. Several unexplained minute perforations of the cecum gave rise to a fibrinous peritonitis.
Comment. The hemothorax, which presumably was derived from the trauma of thoracentesis a week prior to death during dicumarol therapy, was a * PA = prothrombin activity.
contributing but not a major cause of death. Congestive heart failure and peritonitis were the major causes of death. The unusual lymphangioma of the liver was an incidental finding, and although pinpoint hemorrhages were found therein, this could hardly be completely attributed to dicumarol as it is rather characteristic of this type of tumor. Case 5.-The patient, R. E., aged 72 years, a hypertensive with previous myocardial infarction, received dicumarol therapy, in spite of chronic nephritis, because of coronary insufficiency, cerebral arteriosclerosis, congestive heart failure, and phlebothrombosis of the left leg veins. On Jan. 26, 1948, after two months of dicumarol therapy, he lost his power of speech and had clonic convulsions. Prothrombin time was thirty-six seconds (12 per cent PA) and after 300 mg. vitamin K were given intravenously during the next thirty-six hours it dropped to twenty-two seconds (35 per cent PA) without further change in spite of 160 mg. vitamin K given during the next twenty-four hours. The spinal fluid was normal. Convulsions recurred and death ensued on the fourth day. At autopsy the heart weighed 800 grams and showed marked fibrosis, and old occlusion of the left coronary artery. The cerebral vessels were markedly sclerotic with a few scattered pin-point hemorrhages in the internal capsule and pons. Bronchopneumonia, hepatic congestion, and renal hypertensive arterial changes were noted. The pancreas was fibrotic and was the seat of a small hemorrhage.
Comment.-The relationship of the pancreatic apoplexy to the terminal clinical state is difficult to evaluate, and it is questionable whether dicumarol induced it. The petechial hemorrhages in the internal capsule and pons, considered to be the cause of death, were possibly due to dicumarol.
Case 6.-The patient, M.S., aged 60 years, a hypertensive, was continued on dicumarol therapy following his third coronary thrombosis and was moderately active in spite of congestive failure. His anginal pain lessened, but after five months, on Sept. 22, 1948, he died suddenly. The prothrombin time nine days earlier was twenty-six seconds (20 per cent PA) and he had continued his weekly dicumarol dosage of 425 milligrams. Autopsy disclosed petechiae, coronary sclerosis, old myocardial infarction, left ventricular aneurysm, mottled subendocardial hemorrhages on the posterior aspect of the septum, but no fresh coronary occlusion or myocardial infarction. Microscopic sections of the mottled areas of the septum disclosed the same degree of hemorrhage that is often found following fatal acute coronary insufficiency which presumably was the cause of death.
Case In seven of eight autopsied patients who had used dicumarol for two to twenty-three months, no toxic changes were found in the liver or kidneys attributable to dicumarol except for the possibility that the microscopic hemorrhage in the hepatic hemangioma in patient 4 might have been due to the dicumarol, although this is unlikely. No evidence of liver or renal injury after one or more years of dicumarol therapy has developed in the living patients.
Clinical Sequel of Living Patients
In the 57 patients remaining on dicumarol, anginal pain has been minimal or absent in nearly all, in spite of their being moderately active in business or home. The willingness of patients to adhere to the regimen faithfully reflects substantial subjective improvement hardly fully attributable to the psychotherapeutic effect of taking dicumarol. Four of the living patients have experienced episodes of acute coronary insufficiency with possible subendocardial infarction followed by recovery without thrombo-embolic complications. The clinical features of one exceptional case, occurring in an elderly woman who developed a third recurrent acute myocardial infarction while dicumarol was in force, follow:
Patient Mrs. J. R., aged 63 years, had survived an attack of myocardial infarction thirteen years previous to development of premonitory signs of coronary thrombosis on Sept. 2, 1948. She was given heparin and dicumarol but continued to have cardiac pain with occasional nausea and vomiting. When the prothrombin time was forty-six seconds (9 per cent PA), fifteen days after crset, following severe pain, the electrocardiogram showed evidence of anterior wall infarction. Complete relief of her pain, much of which was provoked by the gastrointestinal tract, was not obtained. By the sixth week she was able to be slightly ambulant. The prothrombin time was maintained between twenty and thirty-five seconds (40 to 10 per cent PA). On Jan. 19, 1949, she had severe substernal pain when the prothrombin time was thirty seconds (18 per cent PA). The electrocardiogram showed changes indicative of acute anterolateral myocardial infarction. Congestive heart failure and various ectopic rhythms appeared, and heart failure persists four months later, but the patient is able to be ambulant at home with only mild anginal pain.
This patient developed acute myocardial infarction while on dicumarol fifteen days after onset of premonitory signs, and four months later, while on supposedly adequate dicumarol therapy, a frank anterolateral infarction developed. Obviously dicumarolization did not forestall a recurrent attack, and her case demonstrates that the regimen even when carefully followed may fail to prevent coronary thrombosis.
Eleven patients have followed the regimen two years or longer without recurrence although six had multiple previous attacks. The forty-eight hours to sixteen seconds (80 per cent PA). Dicumarol therapy was omitted for five weeks, but was resumed because of an increase in anginal pain, and has not been interrupted again except for dental extractions. In 1947, recurrent upper respiratory infections and bronchitis appeared and pulmonary emphysema developed with reduction in vital capacity. No left ventricular failure has developed although the heart is moderately enlarged with suggestive signs of ventricular aneurysm. The patient lost weight owing to poor appetite and unsatisfactory dentures, and the pulmonary symptoms remained troublesome but improved when he took a holiday trip to Nova Scotia last summer. His dicumarol requirement was remarkably constant (700 to 800 mg. weekly for four years) until the dietary change occurred as described under "Variable Dicumarol Requirement"; since then he has required only 550 to 600 mg. weekly. He was free of any significant anginal pain until January 1949, when after overexertion, business worries, and excessive use of tobacco, he developed moderate substernal pain not associated with additional electrocardiographic changes. His feeling of wellbeing deteriorated somewhat but has improved again during the past four months. The probability is strong that the use of dicumarol has forestalled additional attacks of coronary thrombosis, since the patient experienced three attacks in thirteen months prior to initiating the dicumarol regime over five years ago. (Fig. 2) congestive heart failure, who, after two months of dicumarol therapy, died in coma and convulsions due to petechial hemorrhages in the internal capsule and pons. In only 3 patients was it necessary to abandon the dicumarol regime because of hemorrhage: In one of these patients repeated hematuria associated with urologic disease occurred after five months of therapy; in another hemorrhage into the shoulder joint followed automobile injury after twenty-three months of therapy; in the third, massive, silent gastrointestinal hemorrhage occurred after thirteen months of therapy. This last patient was a which shows the unpredictability of dicumarolinduced bleeding.
Hemorrhagic episodes are not always well correlated with the prothrombin activity. This consideration applies to the 4 patients described above who died and upon whom autopsies were not performed. It is, however, well recognized that sudden death occurs not infrequently in persons with coronary artery disease without the presence of demonstrable acute lesion. In either case the mechanism of the sudden cessation of cardliac activity is probably ventricular standstill or ventricular fibrillation.
The distinct reduction in anginal pain experienced by most of the dicumarolized group calls forth speculation as to the possible mechanism inducing such striking improvement. The probability of increased coronary blood flow due to lessened blood v-iscosity has been men-Since 1944 dicumarol therapy has been continued indefinitely following an attack of acute coronary thrombosis and/or myocardial infartion in 78 patients in the hope of preventing recurrent attacks.
Twelve patients died, but of these only 4 had recurrent coronary thrombosis (8 autopsy studies). Nine patients discontinued therapy. Fifty-seven patients remaining on the regimen are active and doing well with little anginal complaint, and in 10 of these two or three years have passed without an attack, and in one noteworthy patient, who had three previous myocardial infarctions, over five years have passed since the last recurrence. Four of the living patients have experienced episodes of acute coronary insufficiency with possible subendocardial infarction followed by recovery without thrombo-embolic complications. One elderly patient still alive developed a recurrent myocardial infarction while dicumarolized.
Major hemorrhagic episodes occurred in thirteen patients resulting in two fatalities (only one of which could fairly be attributed to the use of dicumarol) and abandonment of the regimen in 3 other patients; the remainder resumed dicumarol treatment satisfactorily. No toxic effect on the kidneys or liver was found in 7 autopsy subjects who had received dicumarol two to twenty-three months, nor has clinical evidence of such toxicity been found in the living patients. The variability in dicumarol requirement from year to year in a few patients has been illustrated.
No conclusions are drawn from this study but actual reduction of frequency of recurrent attacks may eventually be proved. A cooperative five-year study by clinicians in private practice would reveal whether or not the longterm use of an anticoagulant justifies the trouble and risk involved.
